Arden's 10th Anniversary JDRF Walk
Arden was diagnosed with type 1 diabetes just after her second birthday in August of 2006. That October we participated in our first JDRF Walk.
First Walk 2006, Age 2
Yesterday we walked for the tenth consecutive year...
Arden designed her own walk shirt this year to mimic a softball t-shirt. Big thank you to OmniPod for being cool with us using their Podder logo to make the shirt. It was a great day, the weather was perfect and a ton of Arden's friends and teammates came along in support.
i'm trying to decide what to do with the extra shirts...
Diabetes Dance Dare
Dancing is way better than dumping ice on your head...
This is Arden and her friend Nadia doing the Diabetes Dance Dare for the American Diabetes Association. The ADA does so many great things fort he diabetes community including providing legal counsel for children who are being treated poorly at school. #DiabetesDanceDare
I can't dance so I enlisted Arden...
Make your own video today, share on social media and tag #DiabetesDanceDare, @amdiabetesassn and dare three people to make a video of their own.
I'm daring you!
100,000 downloads and counting!
Thank you for listening!
Available everywhere that podcasts are heard...
News: U.K. Airline Pilots Fit to Fly With Type 1 Diabetes
from MedPage - Ed Susman, Contributing Writer, MedPage Today
MUNICH – Commercial airline pilots flying withinsulin-controlled diabetes had no incidents of medical incapacitation in more than 18 months of study, researchers reported here.
Of the 26 insulin-treated pilots flying planes under the U.K. flag, a total of 8,897 blood glucose monitoring values had been recorded during 4,900 flight hours with more than 96% of the cockpit glucose monitoring readings indicating pilots with diabetes were in the "Green Zone" for safety, reported Julia Hine, MD, of the Royal Surrey County Hospital in Guildford, England.
In a presentation at the European Association for the Study of Diabetes, Hine said that for short and medium haul flights -- those of less than 6 hours duration -- 96% of 7,829 blood glucose monitoring readings were within the safe range. For long haul flights, 97% of 1,068 readings were within that "green" range.
The entire article is avail able here.
First Patients Enrolled in Clinical Trial for Omnipod Artificial Pancreas System
Look out future... Here come the Podders!
BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System). The full study will evaluate the use of a personal Model Predictive Control algorithm with the Omnipod platform in 20 adults with type 1 diabetes and is taking place in a clinical research center setting to gather data to be used to evolve the algorithm in subsequent studies leading to FDA submission.
“We are very excited to be participating in Insulet’s artificial pancreas clinical trials,” said Jordan Pinsker, M.D., senior research physician at William Sansum Diabetes Center. “Working with Professor Francis J. Doyle III and Dr. Eyal Dassau, Sansum played a major role in the development of the original UC Santa Barbara Artificial Pancreas algorithm that Insulet acquired. We look forward to contributing to the clinical and development pathway as Insulet takes this promising technology to a commercial product.”
The Omnipod Horizon System will combine best-in-class technologies into one integrated system consisting of an on-body Omnipod tubeless pump, the latest Dexcom continuous glucose monitoring (CGM) technology, a modified version of Insulet’s handheld controller and state-of-the-art security system architecture. Insulet’s Omnipod Horizon System is unique in that the algorithm looks toward the future horizon of blood glucose levels, reacting quickly and efficiently to adjust insulin delivery to optimize outcomes for each user. The system will provide the same proven lifestyle benefits as the current Omnipod System, such as the discreet, reliable, tubeless form factor and up to three days of non-stop insulin delivery to make it easy to stay connected and avoid disruption of insulin delivery during routine activities like exercising and bathing.
“Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer. “With the first clinical study of our innovative artificial pancreas underway, we have taken another important step in fulfilling our mission to improve the lives of people with diabetes.”